MEASURING THE EFFECT OF CANCER ON HEALTH-RELATED QUALITY-OF-LIFE

被引：16
作者：
OSOBA, D
机构：
[1] Division of Communities Oncology, British Columbia Cancer Agency, Department of Medicine, University of British Columbia, Vancouver
来源：
PHARMACOECONOMICS | 1995年 / 7卷 / 04期
关键词：
D O I：
10.2165/00019053-199507040-00005
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
Measuring health-related quality of life in patients with cancer has focused primarily on the development of reliable and valid instruments (questionnaires), and on the effect of chemotherapy in phase III clinical trials. From this research several important lessons have emerged, such as: (i) the need to measure multiple domains; (ii) the importance of self-rating; (iii) the reports of counter-intuitive results; (iv) the ability to quantify the effects of symptoms on health-related quality of life; and (v) the prognostic value of health-related quality of life measurement for survival. Many challenges lie ahead. Among these are the difficulties encountered by medical clinicians in choosing appropriate instruments to measure health-related quality of life, the dilemma of choosing between aggregate scores and domain scores, questions surrounding the significance of results, and whether measurement of health-related quality of life is now at a point where it can be used in routine practice outside of the clinical trials setting, Although further research is required in all of these and other areas, the future for health-related quality-of-life measurement in oncology is promising.
引用
收藏
页码：308 / 319
页数：12
相关论文
共 77 条
  • [1] Osoba D., Lessons learned from measuring health-related quality of life in oncology, J Clin Oncol, 12, (1994)
  • [2] Karnofsky D.A., Abelman W.H., Craves L.F., Et al., The use of nitrogen mustards in palliative treatment of carcinoma, Cancer, 1, (1948)
  • [3] Zubrod C.G., Schneiderman M., Frei E., Et al., Appraisal of methods for the study of chemotherapy of cancer in man: comparative herapeutic trial of nitrogen mustard and triethylene thiophospharamide, J Chronic Dis, 11, pp. 7-33, (1960)
  • [4] Schipper H., Clinch J., McMurray A., Et al., Measuring quality of life of cancer patients: the Functional Living Index — Cancer: development and validation, J Clin Oncol, 2, (1984)
  • [5] Selby P.J., Chapman J-AW, Etazadi-Amoli I., Et al., The development of a method for assessing quality of life in cancer patients, Br J Cancer, 50, pp. 13-22, (1984)
  • [6] Aaronson N.K., Ahmedzai S., Bergman B., Et al., The European Organization for Research and Treatment of Cancer QLQ­C30: a quality-of-life instrument for use in international trials in oncology, J Natl Cancer Inst, 85, (1993)
  • [7] Morrow G.R., Lindke J., Black P., Measurement of quality of life in patients: psychometric analyses of the Functional Living Index — Cancer (FLIC), Qual Life Res, 1, (1992)
  • [8] Bliss J.M., Selby P.J., Robertson B., Et al., A method for assessing the quality of life of cancer patients: replication of the factor structure, Br J Cancer, 65, (1992)
  • [9] Spitzer W.O., Dobson A.J., Hall J., Et al., Measuring quality of life of cancer patients: a concise QL-index for use by physicians, J Chronic Dis, 34, (1981)
  • [10] de Haes J.C.J.M., Ratgever J.V., van der Burg M.E.L., Et al., Evaluation of the quality of life of patients with advanced ovarian cancer treated with combination chemotherapy, The quality of life of cancer patients, (1987)
12345678